Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

3.960 +0.100 (+2.59%)
Streaming Delayed Price Updated: 10:47 AM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aprea Therapeutics Inc

< Previous 1 2 Next >
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at BIO International Convention
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.